ReviewArthritis research & therapy2016
Are estrogen-related drugs new alternatives for the management of osteoarthritis?
Review in Arthritis research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Uncovering the "riddle of femininity" in osteoarthritis: a systematic review and meta-analysis of menopausal animal models and mathematical modeling of estrogen treatment.Osteoarthritis and cartilage · 2023Pooled it
- Investigating the Relationship Between Estrogen Replacement Therapy and Postoperative Complications Following Single-Level Lumbar Fusion: A Propensity Matched Analysis.Global spine journal · 2026Article
- Integrative Proteome-Wide Mendelian Randomization and Multi-Omics Analysis Identify ADM and CFH as Candidate Genes for Osteoarthritis.Biomedicines · 2026Article
- Estrogen deficiency as a common driver and integrative mechanism in osteoporosis‑osteoarthritis comorbidity (Review).Molecular medicine reports · 2026Review
- Raloxifene ameliorates cartilage and subchondral bone microstructural degeneration in the ovariectomy-induced spontaneous postmenopausal osteoarthritis.Frontiers in genetics · 2026Article
- Sex hormones and their receptors in osteoarthritis: current research progress.Annals of joint · 2026Review
- Contribution of Sex-Biased Expressed Genes in Osteoarthritis.Smart medicine · 2025Article
- Raloxifene Is Associated with Total Knee Arthroplasty in Postmenopausal Women: A Comparative Cohort Study.Life (Basel, Switzerland) · 2025Article
- Impact of estrogen replacement therapy on outcomes following total shoulder arthroplasty: a propensity-matched retrospective cohort study of 1,779 patients.JSES international · 2025Article
- Advanced lung cancer inflammation index and its predictive value for all-cause and cardiovascular mortality among osteoarthritis patients: a NHANES-based study from 2001 to 2018.Frontiers in medicine · 2025Article
- The intersection of aging and estrogen in osteoarthritis.npj women's health · 2025Review
- Article
- S-Equol Ameliorates Menopausal Osteoarthritis in Rats through Reducing Oxidative Stress and Cartilage Degradation.Nutrients · 2024Article
- Parathyroid hormone (1-34) retards the lumbar facet joint degeneration and activates Wnt/β-catenin signaling pathway in ovariectomized rats.Journal of orthopaedic surgery and research · 2024Article
- Effect of Osteoporosis Treatments on Osteoarthritis Progression in Postmenopausal Women: A Review of the Literature.Current rheumatology reports · 2024Review
- Sex differences in the radiographic and symptomatic prevalence of knee and hip osteoarthritis.Frontiers in endocrinology · 2024Review
- G protein-coupled receptor 30 activation inhibits ferroptosis and protects chondrocytes against osteoarthritis.Journal of orthopaedic translation · 2024Article
- Lower serum testosterone is associated with increased likelihood of arthritis.Scientific reports · 2023Article
- Mechanotransduction pathways in articular chondrocytes and the emerging role of estrogen receptor-α.Bone research · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a chronic degenerative disease involving multiple physiopathological mechanisms. The increased prevalence of OA after menopause and the presence of estrogen receptors in joint tissues suggest that estrogen could help prevent development of OA. This review summarizes OA research with a focus on the effects of estrogen and selective estrogen receptor modulators (SERMs). Preclinical studies and clinical trials of estrogen therapy have reported inconsistent results. However, almost all studies assessing SERM treatment have obtained more consistent and favorable effects in OA with a relatively safety and tolerability profiles. At present, some SERMs including raloxifene and bazedoxifene have been approved for the treatment of osteoporosis. In summary, estrogen-related agents may exert both a direct effect on subchondral bone and direct and/or indirect effects upon the surrounding tissues, including the articular cartilage, synovium, and muscle, to name a few. Estrogen and SERMs may be particularly favorable for postmenopausal patients with early-stage OA or osteoporotic OA, a phenotype defined by reduced bone mineral density related to high remodeling in subchondral bone. At present, no single drug exists that can prevent OA progression. Although estrogen-related drugs provide insight into the continued work in the field of OA drug administration, further research is required before SERMs can become therapeutic alternatives for OA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.